Dependency (Psychology), Opiate Withdrawal Syndrome, Opioid-Related Disorders, Pain, Chronic
Conditions
Keywords
Buspirone
Brief summary
This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.
Detailed description
Buspirone (Buspar) has shown initial efficacy in reducing symptoms of opioid withdrawal in animal studies and in human patients undergoing a methadone taper. Buspirone may have pharmacologic activity in specific neurotransmitter systems that preclinical evidence suggests may be implicated in the manifestation of opioid withdrawal symptoms. Administration of buspirone during an opioid taper may improve outcomes relative to placebo. The goal of this study is to collect preliminary feasibility and efficacy data from a sample of patients undergoing clinically-indicated opioid tapering. Participant enrollment will occur at the beginning of their residential stay on the Pain Treatment Unit at Johns Hopkins Hospital. Participants will be randomly assigned to receive buspirone (15 milligrams, three times daily, for daily dose of 45 milligrams) or placebo. Daily assessments for withdrawal and requests for additional symptomatic medications will be evaluated as evidence of initial efficacy. Feasibility measures include willingness to participate and study retention.
Interventions
DRUGBuspirone oral capsule
15 milligrams, three times daily
DRUGPlacebo oral capsule
0 milligrams (placebo), three times daily
Sponsors
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blind placebo controlled study. Patients are randomized to receive either active buspirone or placebo, each of which is over-encapsulated to support blinding.
Intervention model description
Patient completing a residential stay on the Pain Treatment Unit in which this study is being conducted will be enrolled and randomly assigned to receive either buspirone or placebo.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Be at least 18 years old * Be undergoing taper of prescribed opioid pain medications at the study site
Exclusion criteria
* Being pregnant or breastfeeding * Past 7-day use of grapefruit juice or other strong Cytochrome (CYP) P450 inhibitors or inducers * Have medical or psychiatric condition that is contraindicated with buspirone administration * Current suicidality as assessed by clinic staff or the Columbia Suicide Severity Rating Scale
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Taper Completion | 28 days | Final day on which participant is enrolled in the clinic |
| Opioid Withdrawal Symptom Severity | 28 days | Daily ratings of the Subjective Opiate Withdrawal Scale (SOWS)Total Score. The SOWS is a self-administered scale for grading opioid withdrawal symptoms. It contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely), and takes less than 10 minutes to complete. |
Countries
United States
Outcome results
None listed